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ABSTRACT
Background    The purpose of this study was to inves-
tigate the relationship between preoperative FDG-PET 
parameters and the World Health Organization (WHO) 
classification or Masaoka staging system of thymic epi-
thelial tumors.
Methods    We retrospectively reviewed 32 patients with 
histologically proven thymic epithelial tumors who un-
derwent FDG-PET/CT before surgical resection. FDG-
PET parameters, including the maximum standardized 
uptake value (SUVmax), metabolic tumor volume 
(MTV), and total lesion glycolytic activity (TLG), were 
measured. These PET parameters were compared in the 
Masaoka staging system and WHO classification. A re-
ceiver operating characteristics (ROC) analysis was per-
formed to identify the cut-off values of PET parameters 
for the accurate differentiation of early and advanced 
stages in the Masaoka staging system.
Results    There were 17 low-risk thymomas (1 type A, 
9 type AB, and 7 type B1), 8 high-risk thymomas (4 type 
B2 and 4 type B3), and 7 thymic carcinomas (7 squa-
mous cell carcinoma). Their Masaoka stages were as fol-
lows: 24 in the early stage (stages I and II) and 8 in the 
advanced stage (stage III). Regarding the WHO classifi-
cation, only SUVmax showed a significant difference (P 
< 0.05). In the Masaoka stage, all PET parameters were 
significantly higher in the advanced stage than in the 
early stage (P < 0.05). In the ROC analysis to predict the 
early and advanced stages in thymic epithelial tumors, 
the area under the curve was the highest for TLG among 
the PET parameters examined and the cut-off value of 
TLG for discriminating the early from advanced stage 
with maximal sensitivity and specificity was 30.735.
Conclusion    Although volumetric PET parameters, 
such as MTV and TLG, did not correlate with the WHO 
classification, a significant correlation was observed 
between SUVmax and the WHO classification. In the 
Masaoka staging system, volumetric PET parameters 
may achieve more precise staging than SUVmax. 
Key words    fluorodeoxyglucose F18; positron emission 
tomography computed tomography; thymic epithelial 
tumor
Thymic epithelial tumors are the most common primary 
neoplasms of the anterior mediastinum. The World 
Health Organization (WHO) histological classification 
system for thymic epithelial tumors was proposed in 
1999 and revised in 2015,1, 2 and divides thymic epithe-
lial tumors into six subtypes: thymoma types A, AB, 
B1, B2, and B3 and thymic carcinoma, based on the 
morphology of epithelial cells and the lymphocyte-to 
epithelial cell ratio.2 A poor prognosis was previously 
reported to be slightly more common according to type 
in the following order: low-risk thymomas (types A, AB, 
and B1), high-risk thymomas (types B2 and B3), and 
thymic carcinomas.3–5 Another prognostic factor for thy-
mic epithelial tumors, the Masaoka staging system, as 
modified by Koga et al., is the most popular staging sys-
tem, is based on the level of invasion, and is divided into 
stages I, IIA, IIB, III, IVA, and IVB.6, 7 The Masaoka 
staging system has a greater impact on survival than the 
WHO classification.3, 8 The preoperative identification of 
the histological subtype and tumor stage has important 
implications on the management, strategy, and prognosis 
of thymic epithelial tumors. 
 Positron emission tomography (PET) using fluorine-
18 fluorodeoxyglucose (FDG) has emerged as a pow-
erful diagnostic tool for the diagnosis, staging, and 
restaging of several malignancies. Previous studies 
reported FDG-PET/CT values for predicting histological 
subtypes or tumor stages in patients with thymic epi-
thelial tumors.9–15 The maximum standardized uptake 
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value (SUVmax) is a reproducible imaging biomarker on 
PET/CT. Newly suggested volumetric parameters, such 
as the metabolic tumor volume (MTV) and total lesion 
glycolytic activity (TLG), have recently been reported 
as additional diagnostic and prognostic biomarkers in 
various malignant tumors16–19; however, few studies have 
examined the relationship between PET volumetric 
parameters and thymic epithelial tumors.20–23
 The purpose of the present study was to investigate 
the relationships between preoperative PET parameters, 
including SUVmax and other volumetric parameters, 
and the WHO classification or Masaoka staging system 
in patients with resected thymic epithelial tumors.
MATERIALS AND METHODS
Patient Population
Our Institutional Review Board approved this retrospec-
tive study (IRB number: 1601A109). The requirement 
to obtain informed consent was waived. This study was 
a retrospective study of consecutive patients undergoing 
combined FDG-PET/CT between March 2007 and 
December 2015 in our hospital. Thirty-two patients (9 
males and 23 females; age range, 31–81 years; mean 
± SD, 61.7 ± 13.0 years) with thymic epithelial tumors 
underwent FDG-PET/CT before initial surgery. A de-
finitive diagnosis of thymic epithelial tumors had been 
established in all patients. None of the patients had a his-
tory of chemotherapy or radiation therapy before FDG-
PET/CT. 
 All patients underwent surgical resection with tho-
racotomy or video-assisted thoracic surgery. The time 
interval between the PET scan and thymectomy was 
between 5 and 55 days (median: 21 days). All tumors 
were staged according to the Masaoka staging system,6 
and all surgical specimens were reviewed and classi-
fied according to the WHO classification2 (i.e., types 
A, AB, B1, B2, and B3 and thymic carcinoma) by an 
experienced pathologist. All tumors were divided into 3 
subgroups: low-risk thymomas (types A, AB, and B1), 
high-risk thymomas (types B2 and B3), and thymic car-
cinomas. In addition, all tumors were divided into two 
groups by the Masaoka staging system: early stage (stages 
I and II) and advanced stage (stages III and IV).
PET/CT protocols
FDG (290.8 ± 31.6 MBq, mean ± SD), which was 
delivered by Nihon Mediphysics (Tokyo, Japan), was 
administered intravenously after more than 6 hours of 
fasting. All patients underwent whole body imaging ap-
proximately 1 hour after the injection of FDG using an 
integrated PET/CT scanner (Aquiduo; Toshiba Medical 
Systems Corporation, Otawara, Japan). Blood glucose 
levels ranged between 79 and 145 mg/dL (mean: 101.4 
mg/dL) in the FDG-PET/CT study.
 The scanning range was from the top of the skull to 
the mid-thighs of patients. Data acquisition began with 
an attenuation collection CT scan without contrast agent. 
The CT scan was performed using a continuous spiral 
16-detector-row technique with a tube voltage of 120 
kV, gantry rotation speed of 0.5 sec, slice thickness of 
6.0 mm, and beam pitch of 0.9375 under breath holding. 
The X-ray tube current was between 100 and 230 mAs 
(adjusted automatically for body thickness). The PET 
scan was immediately followed by a 2-min emission 
acquisition time at a 162-mm axial field of view per po-
sition. Images were reconstructed with a slice thickness 
of 6.0 mm by the standard ordered-subset expectation 
maximization (OSEM) technique using 14 subsets and 
4 iterations with a 128 × 128 matrix for PET and 512 × 
512 matrix for CT.
Image analysis and PET measurements
An experienced nuclear medicine physician who was 
blinded to the clinical data separately received images 
on a 3D workstation; SYNAPSE VINCENT (Fujifilm, 
Tokyo, Japan). An ellipsoidal volume of interest (VOI) 
was carefully placed to cover the primary thymic 
epithelial tumors with reference to CT images to avoid 
the inclusion of activity from nearby organs with high 
physiological uptake, such as the myocardium.
 The SUVmax of tumors were obtained and re-
corded. MTV indicates the volume of hypermetabolic 
tissue within the region of the gross tumor with an SUV 
greater than the defined threshold, and TLG, which is 
the multiplication of MTV and SUVmean, signifies the 
overall tumor burden. To define the contouring margins 
around the tumor, the defined threshold was considered to 
be 2.5, according to previous studies.22, 23 If the SUVmax 
of a tumor was equal or less than the determined thresh-
old, MTV and TLG were considered to be zero. 
Statistical analysis
Statistical analyses were performed using SPSS for 
Windows software (version 24.0; SPSS Inc., Chicago, 
IL). Clinical and pathological parameters were shown 
as a mean and standard deviation (SD) for continuous 
variables or as a frequency and percentage for categor-
ical variables. Groups were compared using the Mann-
Whitney test or Kruskal-Wallis test. The predictive value 
of PET parameters was assessed by calculating the area 
under the curve of the receiver operating characteristics 
(ROC) curve for univariate logistic regression models. P 
< 0.05 indicated significance.
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Mean ± SD (range) Mean ± SD (range) Mean ± SD (range)
WHO classification
Low-risk thymoma (A-B1) 17 2.9 ± 0.8 (1.2–4.1) 7.0 ± 11.9 (0–46.8) 20.3 ± 35.9 (0–142.3)
Type A 1 4.6 5.0 16.5
Type AB 9 3.0 ± 0.6 (2.4–4.1) 10.5 ± 15.7 (0–46.8) 30.7 ± 47.5 (0–142.3)
Type B1 7 2.7 ± 0.7 (1.2–3.3) 2.8 ± 3.4 (0–8.6) 7.6 ± 9.2 (0–24.3)
High-risk thymoma (B2-B3) 8 3.8 ± 1.9 (1.8–7.5) 28.7 ± 37.7 (0–91.0) 110.8 ± 158.8 (0–382.6)
Type B2 4 4.6 ± 2.5 (2.0–7.5) 52.0 ± 43.9 (0–91.0) 205.6 ± 186.1 (0–382.6)
Type B3 4 3.0 ± 0.9 (1.8–3.8) 5.4 ± 5.2 (0–10.8) 16.0 ± 15.9 (0–33.0)
Carcinoma 7 5.0 ± 1.4 (3.7–8.0) 73.0 ± 145.5 (2.7–396.5) 229.5 ± 434.8 (9.5–1181.6)
Masaoka staging system
Early stage (I-II) 24 3.2 ± 1.1 (1.2–5.6) 9.7 ± 20.1 (0–91.0) 31.6 ± 73.0 (0–342.2)
Stage I 13 2.6 ± 0.7 (1.2–3.6) 4.3 ± 7.1 (0–25.0) 12.1 ± 20.2 (0–71.0)
Stage II 11 3.8 ± 1.1 (2.5–5.6) 15.9 ± 28.1 (0.1–91.0) 54.6 ± 103.4 (0.3–342.2)
Advanced stage (III-IV) 8 4.8 ± 1.9 (2.7–8.0) 78.6 ± 132.6 (2.7–396.5) 260.6 ± 399.6 (9.5–1181.6)
Stage III 8 4.8 ± 1.9 (2.7–8.0) 78.6 ± 132.6 (2.7–396.5) 260.6 ± 399.6 (9.5–1181.6)
All values are expressed as the mean ± standard deviation. MTV, metabolic tumor volume; PET, positron emission tomography; SD, 
standard deviation; SUVmax, maximum standardized uptake value; TLG, total lesion glycolytic activity; VOI, volume of interest; WHO, 
World Health Organization.
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Fig. 1. Box-plot showing the relationship between the WHO clas-
sification and PET parameters. There was significant difference in 
SUVmax, however, there were no significant differences in MTV 
and TLG. Circles and stars represent extreme values. A: SUVmax. 
B: MTV. C: TLG. MTV, metabolic tumor volume; PET, positron 
emission tomography; SUVmax, maximum standardized uptake 
value; TLG, total lesion glycolytic activity; WHO, World Health 
Organization.
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C	 P < 0.05 



























Fig. 2. Box plots showing the relationship between PET param-
eters and the Masaoka staging system. All PET parameters were 
significantly higher in the advanced stage than in the early stage. 
Circles and stars represent extreme values. A: SUVmax. B: MTV. 
C: TLG. MTV, metabolic tumor volume; PET, positron emission 
tomography; SUVmax, maximum standardized uptake value; 
TLG, total lesion glycolytic activity.
Fig.3







Fig. 3. ROC curve analysis for discriminating early stage from 
advanced stage. The AUC of TLG was the highest for discriminat-
ing the early stage from the advanced stage. AUC, area under the 
curve; MTV, metabolic tumor volume; ROC, receiver operating 
characteristics; SUVmax, maximum standardized uptake value; 
TLG, total lesion glycolytic activity.
RESULTS
Thirty-two thymic epithelial tumors, including 17 low-
risk thymomas (1 type A, 9 type AB, and 7 type B1), 
8 high-risk thymomas (4 type B2 and 4 type B3), and 
7 thymic carcinomas (7 squamous cell carcinomas), 
were evaluated in the present study. The distribution of 
tumors according to the simplified WHO classification 
and Masaoka staging system are shown in Table 1. The 
proportion of invasive tumors (stages I, II, and III) with 
reference to the subtype of the Masaoka staging system 
were 13, 11, and 8 patients, respectively. In all patients, 
the mean and SD of SUVmax, MTV, and TLG were 3.6 
± 1.5, 26.9 ± 72.0, and 88.7 ± 223.9, respectively.
 Patients were grouped into low-risk thymoma, high-
risk thymoma, and thymic carcinoma according to 
the WHO classification, and comparisons of the PET 
parameters of tumors are shown in Fig. 1. The mean 
SUVmax was 2.9 ± 0.8 for low-risk thymoma, 3.8 ± 
1.9 for high-risk thymoma, and 5.0 ± 1.4 for thymic 
carcinoma. These differences were significant (P < 0.05). 
Mean MTV and TLG were 7.0 ± 11.9 and 20.3 ± 35.9 
for low-risk thymoma, 28.7 ± 37.7 and 110.8 ± 158.8 
for high-risk thymoma, and 73.0 ± 145.5 and 229.5 ± 
434.8 for thymic carcinoma, respectively. There were no 
significant differences in MTV and TLG (P = 0.08 and 
0.07, respectively). Only SUVmax showed a significant 
difference in the WHO classification. 
 Comparisons of PET parameters in the Masaoka 
stage system are shown in Fig. 2. Mean SUVmax, MTV, 
and TLG were 3.2 ± 1.1, 9.7 ± 20.1, and 31.6 ± 73.0 in 
the early stage and 4.8 ± 1.9, 78.6 ± 132.6 and 260.6 ± 
399.7 in the advanced stage, respectively. All PET pa-
rameters were significantly higher in the advanced stage 
than in the early stage (P < 0.05). 
 An ROC analysis was performed to predict the early 
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Fig. 4. A 44-year-old female with low-risk thymoma (type B1, 
Masaoka stage Ⅱ). CT, PET and fusion images show mild FDG 
uptake in anterior mediastinal tumor (arrows). PET parameters 
were as follows; 3.3 for SUVmax, 8.6 for MTV, and 24.2 for TLG. 
A: CT. B: PET. C: fusion image. CT, computed tomography; 
FDG, fluorine-18 fluorodeoxyglucose; MTV, metabolic tumor vol-
ume; PET, positron emission tomography; SUVmax, maximum 




Fig. 5. A 49-year-old female with thymic carcinoma (Masaoka 
stage Ⅲ). CT, PET and fusion images show strong FDG uptake 
in anterior mediastinal tumor (arrows). PET parameters were as 
follows; 7.1 for SUVmax, 396.5 for MTV, and 1181.6 for TLG. A: 
CT. B: PET. C: fusion image. CT, computed tomography; MTV, 
metabolic tumor volume; PET, positron emission tomography; 
SUVmax, maximum standardized uptake value; TLG, total 
lesion glycolytic activity.
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and advanced stages of thymic epithelial tumors. The 
ROC curve obtained is shown in Fig. 3. The area under 
the curve (AUC) of each PET parameter was as follows: 
0.776 for SUVmax, 0.849 for MTV, and 0.854 for TLG. 
The AUC of TLG was the highest for discriminating 
the early stage from the advanced stage. The cut-off 
value of TLG for discriminating the early stage from the 
advanced stage with maximal sensitivity and specificity 
was 30.735. 
 The representative FDG-PET/CT images were 
shown in Figs. 4 and 5, respectively.
DISCUSSION
The present results indicate that volumetric PET pa-
rameters have potential as metabolic and functional 
biomarkers in the Masaoka stage system for thymic epi-
thelial tumors. FDG uptake and PET volumetric param-
eters for advanced stage thymic epithelial tumors were 
higher than those for early stage thymic epithelial tu-
mors. Regarding the WHO classification, only SUVmax 
correlated well with the WHO classification of thymic 
epithelial tumors, whereas volumetric parameters such 
as MTV and TLG did not. 
 Regarding predictions of the Masaoka stage, previ-
ous studies reported a correlation between the Masaoka 
staging system and SUVmax of thymic epithelial 
tumors.12, 22, 24, 25 Our results also revealed significant 
differences in PET parameters between the early and 
advanced stages. SUVmax, MTV, and TLG were sig-
nificantly higher in the advanced stage than in the early 
stage, and the AUC of MTV and TLG were higher than 
that of SUVmax. The Masaoka staging system evaluates 
the local extent of a tumor based largely on surgical 
findings; therefore, the tumor size may guarantee the tu-
mor extent. SUVmax is recognized as a PET parameter 
related to tumor invasiveness; however, it is a single-pixel 
value representing the most intense FDG uptake in a 
tumor. Volumetric parameters such as MTV and TLG 
define the volume of a tumor based on the distribution 
of metabolic activity, and may be a better marker for the 
Masaoka staging system than SUVmax. MTV signifies 
the volume of the tumor tissue with an increased FDG 
uptake over a certain threshold, while TLG delineates 
the overall tumor burden of FDG uptake. Therefore, 
TLG might be more effective in differentiation between 
early and advanced stages. In the present study, the cut-
off value of TLG for discriminating the early stage from 
the advanced stage was 30.735. Several studies evaluated 
the relationship between TLG and the Masaoka staging 
system for thymic epithelial tumors.20–22 However, to our 
knowledge, there were no studies mentioning a cut-off 
value.
 A number of studies have evaluated the usefulness 
of FDG-PET/CT for predicting the grade of malignancy 
according to the WHO classification and outcomes in 
patients with thymic epithelial tumors9–15; most reported 
that SUVmax was useful for differentiating thymomas 
from thymic carcinomas.9, 10, 13, 15, 23 In contrast, controver-
sy surrounds the ability of FDG-PET/CT to differentiate 
high-risk thymomas from low-risk thymomas. SUVmax 
has been shown to differentiate low-risk thymomas 
from high-risk thymomas,11–13, 26, 27 whereas other studies 
reporting conflicting data9, 10, 23, 28 possibly because of 
a marked overlap in FDG uptake. The present results 
demonstrated that only SUVmax differentiated low-
risk and high-risk thymomas from thymic carcinomas, 
whereas other volume-dependent parameters did not, 
which is consistent with previous findings.22 SUVmax 
represents the highest point of metabolic activity, re-
flecting the greatest biologically aggressiveness, while 
volumetric parameters such as MTV and TLG indicate 
the tumor volume and glycolysis with increased tumor 
aggressiveness, respectively. Therefore, we hypothesized 
that volumetric parameters may be more useful than 
SUVmax for evaluating tumor invasiveness. Based on 
the present results, we considered that tumor size does 
not necessarily reflect tumor invasiveness. SUVmax is 
still the best predictor among several PET parameters in 
the era of volume-dependent parameters. 
 Our study is limited by the relatively small number 
of surgical cases and its retrospective design, which may 
have weakened the statistical power and contributed to 
selection bias. Furthermore, there were no patients with 
stage IV in our study group. We were unable to predict 
the outcomes of patients with thymic epithelial tumors 
because of the long follow-up period required. Further 
studies with larger numbers of patients and longer follow-
ups are needed to evaluate the usefulness of FDG-PET/
CT for predicting patient outcomes.
 In conclusion, although volumetric PET parameters 
such as MTV and TLG did not correlate with the WHO 
classification, a significant correlation was observed 
between SUVmax and the WHO classification. In the 
Masaoka staging system, volumetric PET parameters 
may achieve more precise staging than SUVmax. FDG-
PET/CT parameters may be useful for predicting the 
histological subtype and tumor stage of thymic epithelial 
tumors. 
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